Dppa1 Inhibitors
Dppa1, predicted to be involved in phosphatidylserine binding and functioning as a virus receptor, plays crucial roles in cellular processes such as phagocytosis, engulfment, and positive regulation of mast cell activation. Positioned on the cell surface and expressed in diverse structures, including the nervous system and adrenal gland, Dppa1 is integral to various biological functions. Its ability to bind phosphatidylserine underscores its involvement in cellular recognition and signaling, potentially influencing processes like apoptotic cell clearance and viral interactions. Moreover, its participation in mast cell activation highlights its importance in the immune response, particularly in orchestrating the release of mediators that modulate inflammation and host defense.
The general mechanisms of inhibiting Dppa1 involve targeting specific signaling pathways and molecular components associated with its functions. Direct inhibitors focus on disrupting key kinases like Syk, Src family kinases, and Rac1, which play essential roles in the downstream cascades related to mast cell activation and phagocytosis. These inhibitors act by interfering with the phosphorylation events and molecular interactions that are integral to Dppa1's functions on the cell surface. On the other hand, indirect inhibitors operate by modulating broader pathways such as PI3K/AKT, MAPK/ERK, p38 MAPK, PDGFR, and STAT3. By influencing these pathways, they impact the overall cellular environment, leading to an attenuation of Dppa1's roles in positive regulation of mast cell activation and other associated processes. Understanding these intricate mechanisms provides insights into potential strategies for manipulating Dppa1, shedding light on the complex interplay of molecular events that govern essential cellular functions.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, a PI3K inhibitor, indirectly inhibits Dppa1 by targeting the PI3K/AKT pathway. It modulates phosphatidylinositol-3,4,5-trisphosphate (PIP3) levels, influencing downstream signaling and attenuating Dppa1's role in positive regulation of mast cell activation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin, a PI3K inhibitor, indirectly inhibits Dppa1 by disrupting the PI3K/AKT pathway. It blocks PIP3 production, impacting downstream signaling and impeding Dppa1's involvement in positive regulation of mast cell activation. | ||||||
R406 | 841290-81-1 | sc-364595 sc-364595A | 2 mg 10 mg | $160.00 $370.00 | 16 | |
R406, a Syk kinase inhibitor, directly targets Syk kinase, disrupting the downstream cascade. It impedes Dppa1's role in positive regulation of mast cell activation by interrupting the signaling pathway triggered by Syk kinase. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2, a Src family kinase inhibitor, directly targets Src family kinases, inhibiting their activity. It disrupts the signaling cascades involving Src family kinases and attenuates Dppa1's role in positive regulation of mast cell activation. | ||||||
Tyrphostin B42 | 133550-30-8 | sc-3556 | 5 mg | $26.00 | 4 | |
AG-490, a JAK2 inhibitor, directly targets JAK2, affecting downstream signaling pathways. It interferes with the JAK2-mediated signaling involved in positive regulation of mast cell activation by Dppa1. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580, a p38 MAPK inhibitor, directly targets p38 MAPK, modulating its activity. It interferes with the p38 MAPK-mediated signaling cascades, attenuating Dppa1's involvement in positive regulation of mast cell activation. | ||||||
LY2228820 | 862507-23-1 | sc-364525 | 5 mg | $191.00 | 1 | |
LY2228820, a p38 MAPK inhibitor, directly targets p38 MAPK, disrupting its downstream signaling. It attenuates Dppa1's role in positive regulation of mast cell activation by impeding the p38 MAPK-mediated signaling cascades. | ||||||
ALK5 Inhibitor II | 446859-33-2 | sc-221234 sc-221234A sc-221234B sc-221234C sc-221234D sc-221234E sc-221234F | 1 mg 5 mg 10 mg 50 mg 100 mg 500 mg 1 g | $75.00 $150.00 $215.00 $650.00 $1224.00 $4296.00 $7818.00 | 8 | |
NSC 23766, a Rac1 inhibitor, directly targets Rac1, modulating its activity. It disrupts the signaling cascades involving Rac1 and attenuates Dppa1's role in positive regulation of mast cell activation. | ||||||
Crenolanib | 670220-88-9 | sc-364470 sc-364470A | 5 mg 10 mg | $600.00 $1000.00 | ||
Crenolanib, a PDGFR inhibitor, indirectly inhibits Dppa1 by targeting PDGFR-mediated signaling pathways. It disrupts downstream cascades, attenuating Dppa1's role in positive regulation of mast cell activation. | ||||||
AZD1208 | 1204144-28-4 | sc-503188 | 10 mg | $316.00 | 1 | |
AZD1208, a STAT3 inhibitor, indirectly inhibits Dppa1 by targeting the STAT3 signaling pathway. It modulates STAT3 activity, influencing downstream signaling and attenuating Dppa1's role in positive regulation of mast cell activation. | ||||||